Knight Therapeutics (TSE:GUD)
TSX:GUD
Holding TSE:GUD?
Track your performance easily

Knight Therapeutics (GUD) Financial Statements

85 Followers

Knight Therapeutics Financial Overview

Knight Therapeutics's market cap is currently ―. The company's EPS TTM is C$-0.214; its P/E ratio is -28.65; Knight Therapeutics is scheduled to report earnings on November 7, 2024, and the estimated EPS forecast is C$0.02. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total RevenueC$ 95.57MC$ 86.60MC$ 74.20MC$ 81.50MC$ 89.91M
Gross ProfitC$ 47.34MC$ 41.70MC$ 34.22MC$ 40.18MC$ 37.49M
EBITC$ 3.00MC$ -4.57MC$ -22.06MC$ 11.50MC$ 3.22M
EBITDAC$ 16.17MC$ 8.01MC$ -10.60MC$ 25.20MC$ 15.37M
Net Income Common StockholdersC$ -1.94MC$ -4.55MC$ -24.33MC$ 9.59MC$ 1.84M
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsC$ 148.84MC$ 174.27MC$ 154.42MC$ 142.46MC$ 130.50M
Total AssetsC$ 945.36MC$ 968.21MC$ 945.49MC$ 1.01BC$ 1.01B
Total DebtC$ 58.11MC$ 70.09MC$ 69.09MC$ 82.24MC$ 79.20M
Net DebtC$ -90.73MC$ -104.18MC$ -85.33MC$ -60.22MC$ -51.30M
Total LiabilitiesC$ 182.56MC$ 206.32MC$ 198.62MC$ 196.48MC$ 206.54M
Stockholders EquityC$ 762.80MC$ 761.89MC$ 746.87MC$ 814.66MC$ 807.20M
Cash Flow-
Free Cash FlowC$ -18.51MC$ 19.95MC$ 18.75MC$ 14.88MC$ -1.64M
Operating Cash FlowC$ -1.09MC$ 30.88MC$ 18.55MC$ 15.17MC$ -1.49M
Investing Cash FlowC$ 11.75MC$ -24.37MC$ -1.90MC$ 35.76MC$ 4.20M
Financing Cash FlowC$ -11.36MC$ -2.90MC$ -36.40MC$ -11.24MC$ -22.09M
Currency in CAD

Knight Therapeutics Earnings and Revenue History

Knight Therapeutics Debt to Assets

Knight Therapeutics Cash Flow

Knight Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis